1. Home
  2. BNTC vs ELDN Comparison

BNTC vs ELDN Comparison

Compare BNTC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

HOLD

Current Price

$13.71

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.90

Market Cap

300.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNTC
ELDN
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.7M
300.3M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BNTC
ELDN
Price
$13.71
$3.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$27.67
$8.50
AVG Volume (30 Days)
86.2K
1.3M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
80.94
30.67
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.85
$1.35
52 Week High
$16.76
$4.60

Technical Indicators

Market Signals
Indicator
BNTC
ELDN
Relative Strength Index (RSI) 71.65 56.53
Support Level $12.79 $3.35
Resistance Level $14.35 $4.09
Average True Range (ATR) 0.74 0.30
MACD 0.32 0.04
Stochastic Oscillator 96.74 43.70

Price Performance

Historical Comparison
BNTC
ELDN

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Share on Social Networks: